{"altmetric_id":4688652,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Masonic Cancer Center, University of Minnesota"],"first_seen_on":"2015-10-28T12:53:49+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1428697800,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00889408"],"nct_id":"NCT00889408","pubdate":"2009-04-26T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma","type":"clinical_trial_study_record"},"altmetric_score":{"score":5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":5},"context_for_score":{"all":{"total_number_of_other_articles":4980609,"mean":5.8933407017814,"rank":927787,"this_scored_higher_than_pct":80,"this_scored_higher_than":4030117,"rank_type":"exact","sample_size":4980609,"percentile":80},"similar_age_3m":{"total_number_of_other_articles":188250,"mean":9.9841920435169,"rank":43958,"this_scored_higher_than_pct":76,"this_scored_higher_than":143928,"rank_type":"exact","sample_size":188250,"percentile":76},"this_journal":{"total_number_of_other_articles":13059,"mean":4.3781540817889,"rank":3065,"this_scored_higher_than_pct":75,"this_scored_higher_than":9851,"rank_type":"exact","sample_size":13059,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":684,"mean":4.8675549048316,"rank":159,"this_scored_higher_than_pct":76,"this_scored_higher_than":524,"rank_type":"exact","sample_size":684,"percentile":76}}},"demographics":[],"counts":{"total":{"posts_count":1},"blogs":{"unique_users_count":1,"unique_users":[790],"posts_count":1}},"posts":{"blogs":[{"title":"Study Shows Genetically Engineered Immunotoxin Found to be Safe and Clinically Effective in Patients With B-cell Malignancies","url":"http:\/\/oncozine.com\/xn\/detail\/2830291:BlogPost:30702","license":"public","citation_ids":[4688652,4688653],"posted_on":"2015-04-10T20:30:00+00:00","summary":"According to phase I clinical trial data published in Clinical Cancer Research, a journal published by American Association for Cancer Research (AACR), a new bispecific ligand-directed diphtheria toxin called DT2219 was found to be safe and clinically effe","author":{"name":"Everyone's Blog Posts - Onco'Zine","url":":\/\/\/","description":""}}]}}